about
DNA replication meets genetic exchange: chromosomal damage and its repair by homologous recombinationProcessing of damaged DNA ends for double-strand break repair in mammalian cellsAntifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug actionEffect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysisInhibition of human immunodeficiency virus integrase by bis-catecholsInhibition of human topoisomerase II in vitro by bioactive benzene metabolitesDysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancerRecombinational repair of DNA damage in Escherichia coli and bacteriophage lambdaA phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.Mutation of the zebrafish nucleoporin elys sensitizes tissue progenitors to replication stress.Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationA terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning.Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitorsRepair of DNA strand breaks in a minichromosome in vivo: kinetics, modeling, and effects of inhibitors.Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathwayAcidic pH induces topoisomerase II-mediated DNA damage.Functions of Fun30 chromatin remodeler in regulating cellular resistance to genotoxic stressThe Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer CellsSequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative.Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase.Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging.Expression of anionic glutathione S transferase (GST pi) gene in carcinomas of the uterine cervix and in normal cervices.Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalphaInhibition of cytotoxic T lymphocyte-induced target cell DNA fragmentation, but not lysis, by inhibitors of DNA topoisomerases I and II.Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicityA quantitative shRNA screen identifies ATP1A1 as a gene that regulates cytotoxicity by aurilide B.Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.Autonomous parvovirus DNA replication requires topoisomerase I and its activity is increased during infection.Integration of simian virus 40 into cellular DNA occurs at or near topoisomerase II cleavage hot spots induced by VM-26 (teniposide).Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging.WRN protects against topo I but not topo II inhibitors by preventing DNA break formationSingle-strand interruptions in replicating chromosomes cause double-strand breaks.High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.Inhibition of cancer antioxidant defense by natural compounds.Purification and characterization of a proteolytic active fragment of DNA topoisomerase I from the brine shrimp Artemia franciscana (Crustacea Anostraca).DNA of a circular minichromosome linearized by restriction enzymes or other reagents is resistant to further cleavage: an influence of chromatin topology on the accessibility of DNA.Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.
P2860
Q24630816-D06FB3F3-1437-46C2-B482-9FF857577A3FQ28000148-4E8D28F7-C1C4-4C5B-9C36-EEF73F49BBC0Q28343624-7E0FB564-953F-409F-958D-733ACEC1270FQ28363738-9B8989C2-E969-4B56-9B16-F37AB3E8B570Q28368086-8AAB119E-8856-438C-B16E-E5FAF00B1700Q28379582-B4DD0E74-F265-4B2C-A2A6-F9438E88CA62Q28469051-AC4456E0-36E3-482E-903A-488F67CC9C6AQ29619755-1812A984-08EE-4A8A-956E-6DF56559AD27Q33374599-40B60C29-1AE6-4123-AE2B-40484AA5B835Q33381633-1B57ACD0-30A4-4B2B-AE52-4ED1C614292BQ33495553-B62C3D9F-519D-4A04-B6FA-A085DD4A312CQ33711507-C6CE8C65-50C1-42B6-8D10-855EADFAB89EQ34051008-EA12A5FF-4FA7-4E5B-A770-5384C9F12CC0Q34575146-662A05E6-F058-46B4-91B1-70C077F268E5Q34789076-E3777DC5-24A3-48E1-9FD2-B6F00858CA81Q34868039-FFFA8E7D-C82A-4F0A-B95B-8ACCD7171655Q34982407-16D04509-C95E-4288-8FFC-629DBBDA6128Q35586091-6CD3D374-E550-4EDC-A120-6C2D8E4CD00EQ35683541-A28A63AF-C5F0-41D8-8EBC-F2DA8EE5A783Q35765484-840FAD2B-2335-45CE-B1DC-DDB642852CACQ35890421-1C18AE96-2F29-403A-ADEC-111F97B2986EQ35955209-CEAA70E4-06B5-4F75-8AA8-952555F5EA29Q35976079-6AB64906-D43E-4F75-AC79-AF38DCCC7411Q35982922-A8059584-5108-4099-9B5E-2806C7AB2A6DQ36118901-2108BD5E-FDBB-4E67-B5EA-FCEE5CC92A1EQ36230793-D3A2D269-BC43-480A-8B5A-448DA0620F2AQ36332186-2042D875-73DF-43C5-A6AC-DA443451E7C5Q36374317-0DC9AAE0-0B17-4CDD-AFD0-7CB88B3C36E0Q36431537-DCF0A42E-5EA8-41EB-90AB-5CB927779B96Q36431807-C86BE83B-D313-4493-8382-03492680EEA4Q36683177-4ABC1726-3055-4909-9212-F5759673DCBAQ36823513-53F9CA34-0973-4E34-876D-1CB3EB6B7FD2Q36995530-23FE5305-76DB-4F75-8E6B-9886CB3BE1EEQ37021622-301B7F15-7728-4FCD-AAE0-2B42636A27FCQ37093293-0531E73D-910F-45F7-8D1E-7B05C90946FCQ37269734-C2277F5B-A3C7-401D-8038-60A35AB0F4CCQ37716657-CAD9C5C5-3B27-4E81-BFCD-33B531F2A53EQ38330498-2254B36B-9551-4D9C-B837-8184B55B27E5Q39305253-3524FFD5-673B-4E20-9210-4388BEF0D59FQ39998037-6BDA5238-F509-4A49-9CB9-8C04716E6E13
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Topoisomerase-targeting antitumor drugs.
@en
type
label
Topoisomerase-targeting antitumor drugs.
@en
prefLabel
Topoisomerase-targeting antitumor drugs.
@en
P1476
Topoisomerase-targeting antitumor drugs.
@en
P2093
P304
P356
10.1016/0304-419X(89)90041-3
P407
P577
1989-12-01T00:00:00Z